BETA vs EXPO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BETA Technologies exhibits weak financial health per the Piotroski F-Score of 4/9, indicating a fragile operational foundation despite strong revenue growth. The company's profitability metrics are severely impaired, with a negative operating margin of -1210.42% and a negative ROE of -66.19%, signaling deep operational inefficiencies. Although the firm shows robust revenue growth (150.90% YoY) and a high gross margin (72.20%), these are not translating into earnings or cash flow. The absence of a Graham Number and intrinsic value, combined with a forward P/E of -6.24, reflects a market pricing premium based on speculative growth rather than fundamentals. The lack of analyst consensus on target price and neutral insider activity further undermine conviction.
EXPO shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 9/9). Key strengths include strong valuation and growth metrics. Price trades at a 60.8% premium to fair value estimate ($41.50), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
BETA vs EXPO: Head-to-Head Comparison
This page compares BETA Technologies, Inc. (BETA) and Exponent, Inc. (EXPO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.